Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance

Oncogene

Volumn 29, Issue 33, 2010, Pages 4648-4657

  Plaza Menacho, I ^a,c   Morandi, A ^a   Robertson, D ^a   Pancholi, S ^a   Drury, S ^a,b   Dowsett, M ^a,b   Martin, L A ^a   Isacke, C M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

breast cancer; endocrine resistance; endocrine therapy; estrogen receptor; RET; tamoxifen

Indexed keywords

ESTROGEN RECEPTOR ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN RET; SERINE; TAMOXIFEN; AFIMOXIFENE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR; MTOR PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

ARTICLE; BREAST CANCER; DOWN REGULATION; DOWNSTREAM PROCESSING; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-RET; SIGNAL TRANSDUCTION; TAMOXIFEN; TOR SERINE-THREONINE KINASES;

EID: 77955927946     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.209     Document Type: Article

References (54)

1. Abe Y, Yoon SO, Kubota K, Mendoza MC, Gygi SP, Blenis J. (2009). p90 ribosomal S6 kinase and p70 ribosomal S6 kinase link phosphorylation of the eukaryotic chaperonin containing TCP-1 to growth factor, insulin, and nutrient signaling. J Biol Chem 284: 14939-14948.
2. Ali S, Coombes RC. (2000). Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasia 5: 271-281.
3. Ali S, Coombes RC. (2002). Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2: 101-112.
4. Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L et al. (2007). Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 99: 694-705.
5. Arpino G, Wiechmann L, Osborne CK, Schiff R. (2008). Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29: 217-233.
6. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E et al. (1992). Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24: 85-95.
7. Berry NB, Fan M, Nephew KP. (2008). Estrogen receptor alpha (ER{alpha}) hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome. Mol Endocrinol 22: 1535-1551.
8. Boulay A, Breuleux M, Stephan C, Fux C, Brisken C, Fiche M et al. (2008). The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer. Cancer Res 68: 3743-3751.
9. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. (2001). Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276: 9817-9824.
10. Chang SB, Miron P, Miron A, Iglehart JD. (2007). Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. J Surg Res 138: 37-44.
11. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D. (2006). Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 66: 3903-3911.
12. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM et al. (2004). Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 10: 8059-8067.
13. Dowsett M, Houghton J, Iden C, Salter J, Farndon J, AHern R et al. (2006). Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 17: 818-826.
14. Esseghir S, Todd SK, Hunt T, Poulsom R, Plaza-Menacho I, Reis-Filho JS et al. (2007). A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer. Cancer Res 67: 11732-11741.
15. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbo-gen BS. (2003). Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144: 4562-4574.
16. Gee JM, Robertson JF, Ellis IO, Nicholson RI. (2001). Phosphoryla-tion of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95: 247-254.
17. Ghayad SE, Bieche I, Vendrell JA, Keime C, Lidereau R, Dumontet C et al. (2008). mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci 99: 1992-2003.
18. Green KA, Carroll JS. (2007). Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat Rev Cancer 7: 713-722.
19. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC et al. (2005). Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23: 2469-2476.
20. Howell A, Dowsett M. (2004). Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. Breast Cancer Res 6: 269-274.
21. Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M et al. (2008). Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13: 91-104.
22. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J, Lannigan DA. (1998a). pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol 18: 1978-1984.
23. Joel PB, Traish AM, Lannigan DA. (1998b). Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J Biol Chem 273: 13317-13323.
24. Johnston SR. (2009). Enhancing the efficacy of hormonal agents with selected targeted agents. Clin Breast Cancer 9(Suppl 1): S28-S36.
25. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H et al. (1995). Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494.
26. Kok M, Holm-Wigerup C, Hauptmann M, Michalides R, Stal O, Linn S et al. (2009). Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer. J Natl Cancer Inst 101: 1725-1729.
27. Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT et al. (2000). Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60: 5887-5894.
28. Leary A, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA et al. (2010). Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 16: 1486-1497.
29. Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M et al. (2007). Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet 3: e87.
30. Lykkesfeldt AE, Madsen MW, Briand P. (1994). Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164 384 and ICI 182 780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 54: 1587-1595.
31. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. (2003). Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 278: 30458-30468.
32. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S et al. (2008). Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68: 826-833.
33. Massarweh S, Schiff R. (2006). Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 13(Suppl 1): S15-S24.
34. Musgrove EA, Sutherland RL. (2009). Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9: 631-643.
35. Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA et al. (2001). Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 8: 175-182.
36. Nicholson RI, McClelland RA, Robertson JF, Gee JM. (1999). Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 6: 373-387.
37. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D. (2001). Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 15: 1344-1359.
38. Osborne CK, Shou J, Massarweh S, Schiff R. (2005). Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11: 865s-887s.
39. Pancholi S, Lykkesfeldt AE, Hilmi C, Banerjee S, Leary A, Drury S et al. (2008). ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr Relat Cancer 15: 985-1002.
40. Perez-Tenorio G, Stal O. (2002). Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86: 540-545.
41. Plaza-Menacho I, Koster R, van der Sloot AM, Quax WJ, Osinga J, van der Sluis T et al. (2005). RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Res 65: 1729-1737.
42. Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, Links TP et al. (2007a). Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 282: 29230-29240.
43. Plaza-Menacho I, van der Sluis T, Hollema H, Gimm O, Buys CH, Magee AI et al. (2007b). Ras/ERK1/2-mediated STAT3 Ser727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation. J Biol Chem 282: 6415-6424.
44. Reis-Filho JS, Steele D, Di Palma S, Jones RL, Savage K, James M et al. (2006). Distribution and significance of nerve growth factor receptor (NGFR/p75(NTR)) in normal, benign and malignant breast tissue. Mod Pathol 19: 307-319.
45. Rogatsky I, Trowbridge JM, Garabedian MJ. (1999). Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J Biol Chem 274: 22296-22302.
46. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J et al. (2007). RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 282: 14056-14064.
47. Sabnis GJ, Macedo LF, Goloubeva O, Schayowitz A, Brodie AM. (2008). Stopping treatment can reverse acquired resistance to letrozole. Cancer Res 68: 4518-4524.
48. Savage K, Lambros MB, Robertson D, Jones RL, Jones C, Mackay A et al. (2007). Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 13: 90-101.
49. Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J et al. (2006). The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 25: 2781-2791.
50. Shim WS, Conaway M, Masamura S, Yue W, Wang JP, Kmar R et al. (2000). Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 141: 396-405.
51. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H et al. (2004). Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96: 926-935.
52. Yamashita H, Nishio M, Toyama T, Sugiura H, Kondo N, Kobayashi S et al. (2008). Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer. Endocr Relat Cancer 15: 755-763.
53. Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ, Holz MK. (2009). S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem 284: 6361-6369.
54. Yue W, Wang JP, Conaway M, Masamura S, Li Y, Santen RJ. (2002). Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology 143: 3221-3229.